COX-2: where are we in 2003?--distinction from NSAIDs becoming blurred.

Arthritis Res Ther · 2003 · PMC165043 · PMID 12723976

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Expressed another way, there were 2.09 versus 4.49 events per 100 patient years of therapy in rofecoxib and naproxen, respectively, which is a highly significant difference.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.